Shasqi

Shasqi is a clinical stage biotech company aiming to revolutionize cancer treatment by leveraging click chemistry, a technology honored with the 2022 Nobel Prize. The company's CAPAC® (Click Activated Protodrugs Against Cancer) platform harnesses click chemistry to deliver high doses of cancer drugs directly to the tumor site while minimizing harm to healthy cells, potentially enhancing the therapeutic index. Shasqi boasts an extensive and diverse library of antibody-mediated tumor-targeting agents and cancer therapeutic payloads, decoupled from each other and reconnected at the tumor site through a click chemistry reaction. Notably, Shasqi is the first company to employ click chemistry in humans. Established in 2015 and headquartered in the United States, the company recently secured a $1.90M grant investment on 08 December 2021, with the National Cancer Institute as the investor. For further information, visit www.shasqi.com.

This insightful analysis conveys Shasqi’s remarkable position within the biotechnology and healthcare industries while highlighting its groundbreaking use of click chemistry in cancer treatment. The recent grant investment from the esteemed National Cancer Institute underscores the industry’s recognition of Shasqi’s innovative approach.